Cyclosporin

1. Front Matter

   Pages i-x

   PDF

2. Inhibitory effects of cyclosporin A on lymphocyte activation

   • John E. Kay

   Pages 1-23

3. Effect of cyclosporin A on the immune response: pivotal role of the interleukin-2/ interleukin-2 receptor autocrine pathway

   • Allan D. Hess

   Pages 24-33

4. Influence of CsA on humoral immunity and on B lymphocyte activation

   • Iris Motta, Paolo Truffa-Bachi

   Pages 34-49

5. The influence of cyclosporin A on T cell activation, cytokine gene expression and cell-mediated immunity

   • Angus W. Thomson, Janet I. Duncan

   Pages 50-81

6. Cyclosporin A and tolerance induction in experimental animals

   • Susan M. L. Lim, David J. G. White

   Pages 82-111

7. Prevention of graft rejection by cyclosporin A in man

   • Michael C. Jones, Graeme R. D. Catto

   Pages 112-144

8. Cyclosporin A and bone marrow transplantation

   • Kerry Atkinson

   Pages 145-158

9. Cyclosporin A and intraocular inflammatory disease

   • John V. Forrester, Janet Liversidge, Hamish M. Towler

   Pages 159-180

10. Cyclosporin A in insulin-dependent diabetes

    • Jean-François Bach

    Pages 181-190

11. Cyclosporin A and skin disease

    • Anne V. Powles, Barbara S. Baker, Lionel Fry

    Pages 191-212

12. Cyclosporin A (Sandimmun®) in autoimmune disorders

    • Beat von Graffenried, David Friend, Nicholas Shand, Wilfried Scheiss, Pentti Timonen

    Pages 213-251

13. Pharmacokinetics of cyclosporin A

    • Joachim Grevel, Barry D. Kahan

    Pages 252-266

14. Cyclosporin A Metabolism and Drug Interactions

    • M. Danny Burke, Fiona Macintyre, D. Cameron, Paul H. Whiting

    Pages 267-302

15. Pathological effects of cyclosporin A in experimental models

    • Paul H. Whiting, Angus W. Thompson

    Pages 303-323

16. Pathological effects of cyclosporin A in clinical practice

    • Sathia Thiru

    Pages 324-364

17. Back Matter

    Pages 365-372

    PDF

Cyclosporin has had a remarkable effect on clinical organ transplantation. Prior to its introduction, considerable advances had been made in the grafting of vital organs, particularly the kidney, heart and liver. In many developed countries, however, transplantation was not considered wo-rthwhile in terms of gain for the investment of resources. The improved results of kidney grafts following the use of cyclosporin has changed this attitude. For all types of organ transplantation, cyclosporin has resulted in an improvement of functional graft survival and has allowed a reduction in steroid dose and, in some cases, no steroids at all. It has permitted the first successful experimental transplantation of the heart and lungs in primate species by Reitz and colleagues and their results were applied directly to the clinic. It was largely due to the introduction of cyclosporin that the Washington Consensus Meeting on Liver Transplantation came to a favourable recommendation and the result has been the proliferation of units performing liver transplantation, approximately fifty in North America and another fifty in Europe, where previously there had been a handful. Having been involved in cyclosporin for organ grafting from the beginning, I have been able to witness these developments which have far exceeded my expectations once the nephrotoxicity of cyclosporin was demonstrated in man. It is fitting that Dr.

• T cell
• bone marrow
• cell
• cytokine
• drug
• kinetics
• metabolism
• pharmacokinetics
• research
• skin
• transplantation

• Immunopathology Laboratory, Department of Pathology, University of Aberdeen, Aberdeen, Scotland

  Angus W. Thomson

Policies and ethics